ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

TSTL Tristel Plc

435.00
-12.50 (-2.79%)
28 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Tristel Plc LSE:TSTL London Ordinary Share GB00B07RVT99 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -12.50 -2.79% 435.00 430.00 445.00 447.50 437.50 447.50 32,309 16:35:03
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Med, Dental, Hosp Eq-whsl 36.01M 4.46M 0.0941 46.49 207.38M

Tristel PLC Commercial collaboration with Parker Laboratories (8400I)

26/03/2018 7:00am

UK Regulatory


Tristel (LSE:TSTL)
Historical Stock Chart


From Mar 2019 to Mar 2024

Click Here for more Tristel Charts.

TIDMTSTL

RNS Number : 8400I

Tristel PLC

26 March 2018

Tristel plc

("Tristel" or "the Company")

Commercial collaboration with Parker Laboratories Inc., USA

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has entered into a manufacturing and marketing agreement with Parker Laboratories Inc., USA ('Parker') whereby Parker will manufacture Tristel's Duo chlorine dioxide foam disinfectant for the North, Central and South American market and will market the product in the ultrasound marketplace throughout the region. This collaboration with Parker prepares Tristel for its entry into the United States infection prevention marketplace in advance of the grant of approval by the United States Environmental Protection Agency ('EPA') for Duo which is expected during the second half of the current financial year.

Parker (www.parkerlabs.com) was founded in 1958 and is family-owned and managed. The company pioneered the development of conductive gels for use in ultrasound. It manufactures its products in a 95,000 sq ft facility in Fairfield, New Jersey and is registered with the United States Food and Drug Administration ('FDA') as a manufacturer of medical devices. All Parker products are manufactured under Good Manufacturing Practice ('GMP') directives. Parker's products are available to ultrasound practitioners in every country throughout the world. Its Aquasonic 100 gel is the market leader in the United States where the company has nationwide distribution through a network of approximately 500 distributors. Parker is also a market leader in the ultrasound market in Canada and throughout Central and South America.

This initiative is part of Tristel's stated intention to enter the North American infection prevention market. This plan was unveiled in the Company's preliminary results announcement in October 2015. In pursuit of this plan, on 30 June 2017 Tristel made a submission for regulatory clearance by the EPA of its Duo chlorine dioxide disinfection foam. Following EPA federal approval, the Company will need to secure state-by-state approval before sales of Duo can commence

The EPA clearance will enable Duo to claim intermediate disinfection of all non-porous surfaces, including those of medical instruments such as ultrasound probes. This is Tristel's core activity worldwide and accounts for approximately 80% of the Company's revenues. In addition, the Company continues to develop two submissions to be made to the FDA for 510(K) clearance in respect of Duo. The 510(K) approval will permit Duo to claim high-level disinfection of medical instruments. It is important to note that in all other markets worldwide, Duo is classified as a high-level disinfectant.

Paul Swinney, CEO of Tristel plc, comments: "We are very pleased to conclude this collaboration with Parker, whose President and main shareholder we first met some fifteen years ago. The company is extremely well-known in ultrasound having been around for so many years under the long-term ownership and management of the Buchalter family. Our collaboration will give us the platform to access the ultrasound marketplace throughout the United States and the Americas, first with our EPA approved Duo product and in due course with our FDA approved Duo."

For further information please contact:

 
 Tristel plc                                   Tel: 01638 721 500 
 Paul Swinney, Chief Executive Officer 
 Liz Dixon, Finance Director 
 
 Walbrook PR Ltd     Tel: 020 7933 8780 or tristel@walbrookpr.com 
 Paul McManus                                  Mob: 07980 541 893 
 Lianne Cawthorne                              Mob: 07854 391 303 
 
 finnCap                                       Tel: 020 7220 0500 
 Geoff Nash/ Giles Rolls (Corporate Finance) 
 Alice Lane (Corporate Broking) 
 

The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.

This information is provided by RNS

The company news service from the London Stock Exchange

END

AGRJAMRTMBTTBMP

(END) Dow Jones Newswires

March 26, 2018 02:00 ET (06:00 GMT)

1 Year Tristel Chart

1 Year Tristel Chart

1 Month Tristel Chart

1 Month Tristel Chart

Your Recent History

Delayed Upgrade Clock